0
World
ViGenCell wins ASCO oral slot with Phase 2 cell therapy data
April 22, 2026
Scroll
Posted 3 hours ago by
ViGenCell has been selected to deliver an official oral presentation at this year’s American Society of Clinical Oncology annual meeting next month, becoming the first Korean company to do so regarding clinical studies of a cell therapy. The company said the study's principal researcher, Dr. Jeon Young-woo, will lead the presentation of the results from its Phase 2 clinical study of VT-EBV-N during the 2026 ASCO annual meeting slated from May 29 to June 2 in Chicago.
VT-EBV-N is an Epstein-Barr
The korea Herald News
Coverage and analysis from South Korea. All insights are generated by our AI narrative analysis engine.
South Korea
Bias: center
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.